PR Newswire
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
📈
AI Sentiment
Highly Positive
9/10
TuHURA Biosciences Inc. News
Latest updates and market news for HURA
1 news
Jan 30 - Feb 5, 2026
Page 1
Share this news page